Intuitive Surgical (NASDAQ: ISRG), a leading medical robotics firm based in the US, has announced that it has received regulatory approval in China for its Ion surgical robot system. Initially approved in the US in 2019, the Ion system is a robotic-assisted, catheter-based platform designed for minimally invasive biopsy procedures deep within the lung. The system utilizes fiber optic shape sensor technology along the catheter’s length to generate precise location and shape information, enhancing the accuracy of the procedure.
Intuitive Surgical is expanding its presence in China through a joint-venture partnership established in 2016 with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), named Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. This strategic collaboration aims to bring Intuitive’s advanced robotics technology to the Chinese market. Following this approval, the company’s Da Vinci Xi surgical robot, a thoracoabdominal endoscopic surgery control system, was launched in China in November 2023 by the joint venture.- Flcube.com
